diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12501diaendo-12501Research ArticleОбзорыReviewРоль ренин-ангиотензиновой системы и ангиотензинпревращающего фермента 2 типа в развитии и течении вирусной инфекции СОVID-19 у пациентов с сахарным диабетомThe role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitushttps://orcid.org/0000-0003-0571-8882ВикуловаОльга КонстантиновнаVikulovaO. K.

к.м.н., доцент

MD, PhD, associate professor

gos.registr@endocrincentr.ruhttps://orcid.org/0000-0001-6953-6928ЗураеваЗамира ТотразовнаZuraevaZamira

к.м.н.

MD, PhD

zuraeva_zamira@mail.ruhttps://orcid.org/0000-0002-1120-8240НиканкинаЛариса ВячеславовнаNikankinaL. V.

к.м.н.

MD, PhD

larisa.nikankina@yandex.ruhttps://orcid.org/0000-0002-5057-127XШестаковаМарина ВладимировнаShestakovaM. V.

д.м.н., профессор, академик РАН

MD, PhD, Professor

nephro@endocrincentr.ruНациональный медицинский исследовательский центр эндокринологиРоссияEndocrinology Research CentreRussian Federation202010082020233242249Copyright © Викулова О.К., Зураева З.Т., Никанкина Л.В., Шестакова М.В., 20202020Викулова О.К., Зураева З.Т., Никанкина Л.В., Шестакова М.В.Vikulova O.K., Zuraeva Z., Nikankina L.V., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12501

Изучение роли ренин-ангиотензиновой системы (РАС) в целом и ангиотензинпревращающего фермента 2 типа (АПФ2) в частности в патогенезе и течении вирусной инфекции, вызванной SARS-CoV-2 (COVID-19), представляет особый интерес. Это связано не только с тем, что АПФ2 является рецептором для проникновения вируса в клетки-мишени. Гиперактивация РАС, характерная для пациентов с артериальной гипертонией, сердечно-сосудистыми заболеваниями и сахарным диабетом, рассматривается в качестве одного из наиболее вероятных факторов более тяжелого течения инфекции у лиц с сопутствующей патологией. Кроме того, влияние медикаментозной блокады РАС посредством ингибиторов АПФ (иАПФ) и блокаторов рецепторов ангиотензина II (БРА) остается одной из наиболее обсуждаемых тем в литературе, ­посвященной COVID-19. В данном литературном обзоре представлены сведения о взаимодействии вируса и основных компонентов РАС и факторах, влияющих на уровень их экспрессии, о влиянии терапии иАПФ и БРА на исходы течения заболевания, а также представлены перспективы лечения данной инфекции с помощью рекомбинантного АПФ2.

The role of renin-angiotensin system (RAS) in general and angiotensin-converting enzyme 2 (ACE2) in particular in the  pathogenesis and course of viral infection caused by SARS-CoV-2 (COVID-19) is of particular interest. This is due not only to the fact that ACE2 is a receptor for the virus the target cells. RAS hyperactivation in patients with arterial hypertension, cardiovascular disease and diabetes mellitus, is considered one of the most important factors for a more severe infection in persons with concomitant pathology. In addition, the effects of PAS blockage with angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs) remains one of the most discussed topics in the literature on COVID-19. This review presents the data on the interaction between the virus and the main components of RAS and the factors influencing their expression level, the impact of ACE ­inhibitors and ARBs therapy on the disease outcome, and presents the perspectives of the treatment with recombinant ACE 2.

SARS-CoV-2COVID-19сахарный диабетренин-ангиотензиновая системаангиотензинпревращающий фермент 2ангиотензин 1-7ангиотензин IIингибиторы ангиотензинпревращающего ферментаблокаторы рецепторов ангиотензина IISARS-CoV-2COVID-19diabetes mellitusrenin-angiotensin systemangiotensin converting enzyme 2angiotensin 1-7¬angiotensin IIangiotensin converting enzyme inhibitorsangiotensin II receptor blockersReferencesGuan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708−1720. doi: https://doi.org/10.1056/NEJMoa2002032Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708−1720. doi: https://doi.org/10.1056/NEJMoa2002032Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi: https://doi.org/10.1001/jama.2020.2648Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi: https://doi.org/10.1001/jama.2020.2648Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: https://doi.org/10.1016/S2213-2600(20)30079-5Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: https://doi.org/10.1016/S2213-2600(20)30079-5Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1–11. doi: https://doi.org/10.1001/jamainternmed.2020.0994Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1–11. doi: https://doi.org/10.1001/jamainternmed.2020.0994Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: https://doi.org/10.1016/j.ijid.2020.03.017Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: https://doi.org/10.1016/j.ijid.2020.03.017Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–821. doi: https://doi.org/10.1177/1932296820924469Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–821. doi: https://doi.org/10.1177/1932296820924469Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and Pre-existing Type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.e3. doi: https://doi.org/10.1016/j.cmet.2020.04.021Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and Pre-existing Type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.e3. doi: https://doi.org/10.1016/j.cmet.2020.04.021Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 2016;351(2):201–211. doi: https://doi.org/10.1016/j.amjms.2015.11.011Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 2016;351(2):201–211. doi: https://doi.org/10.1016/j.amjms.2015.11.011Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26(3-4):259–265. doi: https://doi.org/10.1111/j.1574-695X.1999.tb01397.xGeerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26(3-4):259–265. doi: https://doi.org/10.1111/j.1574-695X.1999.tb01397.xJi HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065–1075. doi: https://doi.org/10.1152/physrev.00013.2020Ji HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065–1075. doi: https://doi.org/10.1152/physrev.00013.2020Fernandez C, Rysä J, Almgren P, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018;284(4):377–387. doi: https://doi.org/10.1111/joim.12783Fernandez C, Rysä J, Almgren P, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018;284(4):377–387. doi: https://doi.org/10.1111/joim.12783Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.е8. doi: https://doi.org/10.1016/j.cell.2020.02.052Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.е8. doi: https://doi.org/10.1016/j.cell.2020.02.052Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134. doi: https://doi.org/10.1128/JVI.02232-10Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134. doi: https://doi.org/10.1128/JVI.02232-10Peci S, Inzirillo F, Peci F. The role of soluble recombinant ACE2 in SARS-COV-2 patients. EC Pulmonology and Respiratory Medicine. 2020;9(7):17–22.Peci S, Inzirillo F, Peci F. The role of soluble recombinant ACE2 in SARS-COV-2 patients. EC Pulmonology and Respiratory Medicine. 2020;9(7):17–22.Xiao L, Sakagami H, Miwa N. ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses. 2020;12(5):491. doi: https://doi.org/10.3390/v12050491Xiao L, Sakagami H, Miwa N. ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses. 2020;12(5):491. doi: https://doi.org/10.3390/v12050491South AM, Tomlinson L, Edmonston D, et al. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305–307. doi: https://doi.org/10.1038/s41581-020-0279-4South AM, Tomlinson L, Edmonston D, et al. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305–307. doi: https://doi.org/10.1038/s41581-020-0279-4Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77(2):301–308. doi: https://doi.org/10.1253/circj.cj-12-1544Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77(2):301–308. doi: https://doi.org/10.1253/circj.cj-12-1544Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–1326. doi: https://doi.org/10.1161/CIRCRESAHA.116.307708Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–1326. doi: https://doi.org/10.1161/CIRCRESAHA.116.307708Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291–294. doi: https://doi.org/10.1016/j.tips.2004.04.001Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291–294. doi: https://doi.org/10.1016/j.tips.2004.04.001Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi: https://doi.org/10.1007/s00134-020-05985-9Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi: https://doi.org/10.1007/s00134-020-05985-9Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247–257. doi: https://doi.org/10.1002/emmm.201000080Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247–257. doi: https://doi.org/10.1002/emmm.201000080Mateo T, Abu Nabah YN, Abu Taha M, et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol. 2006;176(9):5577–5586. doi: https://doi.org/10.4049/jimmunol.176.9.5577Mateo T, Abu Nabah YN, Abu Taha M, et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol. 2006;176(9):5577–5586. doi: https://doi.org/10.4049/jimmunol.176.9.5577Montezano AC, Cat AN, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014;16(6):431. doi: https://doi.org/10.1007/s11906-014-0431-2Montezano AC, Cat AN, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014;16(6):431. doi: https://doi.org/10.1007/s11906-014-0431-2McGonagle D, O’Donnell J, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):e437–e445. https://doi.org/10.1016/s2665-9913(20)30121-1McGonagle D, O’Donnell J, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):e437–e445. https://doi.org/10.1016/s2665-9913(20)30121-1Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(12):2856–2864. doi: https://doi.org/10.1161/ATVBAHA.111.237198Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(12):2856–2864. doi: https://doi.org/10.1161/ATVBAHA.111.237198Lee YB, Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res. 2002;69(1):94–103. doi: https://doi.org/10.1002/jnr.10253Lee YB, Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res. 2002;69(1):94–103. doi: https://doi.org/10.1002/jnr.10253Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, et al. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 2015;172(9):2330–2342. doi: https://doi.org/10.1111/bph.13057Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, et al. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 2015;172(9):2330–2342. doi: https://doi.org/10.1111/bph.13057Li Y, Cao Y, Zeng Z, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep. 2015;5:8209. doi: https://doi.org/10.1038/srep08209Li Y, Cao Y, Zeng Z, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep. 2015;5:8209. doi: https://doi.org/10.1038/srep08209Meng Y, Yu CH, Li W, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway. Am J Respir Cell Mol Biol. 2014;50(4):723–736. doi: https://doi.org/10.1165/rcmb.2012-0451OCMeng Y, Yu CH, Li W, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway. Am J Respir Cell Mol Biol. 2014;50(4):723–736. doi: https://doi.org/10.1165/rcmb.2012-0451OCPai WY, Lo WY, Hsu T, et al. Angiotensin-(1-7) inhibits thrombin-induced endothelial phenotypic changes and reactive oxygen species production via NADPH Oxidase 5 downregulation. Front Physiol. 2017;8:994. doi: https://doi.org/10.3389/fphys.2017.00994Pai WY, Lo WY, Hsu T, et al. Angiotensin-(1-7) inhibits thrombin-induced endothelial phenotypic changes and reactive oxygen species production via NADPH Oxidase 5 downregulation. Front Physiol. 2017;8:994. doi: https://doi.org/10.3389/fphys.2017.00994Santos RA, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505–553. doi: https://doi.org/10.1152/physrev.00023.2016Santos RA, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505–553. doi: https://doi.org/10.1152/physrev.00023.2016Yuan L, Li Y, Li G, et al. Ang(1-7) treatment attenuates β-cell dysfunction by improving pancreatic microcirculation in a rat model of Type 2 diabetes. J Endocrinol Invest. 2013;36(11):931–937. doi: https://doi.org/10.3275/8951Yuan L, Li Y, Li G, et al. Ang(1-7) treatment attenuates β-cell dysfunction by improving pancreatic microcirculation in a rat model of Type 2 diabetes. J Endocrinol Invest. 2013;36(11):931–937. doi: https://doi.org/10.3275/8951Dijkman R, Jebbink MF, Deijs M, et al. Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. J Gen Virol. 2012;93(Pt 9):1924–1929. doi: https://doi.org/10.1099/vir.0.043919-0Dijkman R, Jebbink MF, Deijs M, et al. Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. J Gen Virol. 2012;93(Pt 9):1924–1929. doi: https://doi.org/10.1099/vir.0.043919-0Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clinical Science. 2020;134(5):543–545. doi: https://doi.org/10.1042/CS20200163Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clinical Science. 2020;134(5):543–545. doi: https://doi.org/10.1042/CS20200163Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi: https://doi.org/10.1002/path.1570Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi: https://doi.org/10.1002/path.1570Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: https://doi.org/10.1038/s41368-020-0074-xXu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: https://doi.org/10.1038/s41368-020-0074-xBunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427–2429. doi: https://doi.org/10.1001/jama.2020.8707Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427–2429. doi: https://doi.org/10.1001/jama.2020.8707Xie X, Chen J, Wang X, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166–2171. doi: https://doi.org/10.1016/j.lfs.2005.09.038Xie X, Chen J, Wang X, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166–2171. doi: https://doi.org/10.1016/j.lfs.2005.09.038Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548–551. doi: https://doi.org/10.1002/jmv.25722Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548–551. doi: https://doi.org/10.1002/jmv.25722Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;162:108132. doi: https://doi.org/10.1016/j.diabres.2020.108132Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;162:108132. doi: https://doi.org/10.1016/j.diabres.2020.108132Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20(1):62–68. doi: https://doi.org/10.1097/MNH.0b013e328341164aTikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20(1):62–68. doi: https://doi.org/10.1097/MNH.0b013e328341164aDevaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–435. doi: https://doi.org/10.1016/j.jmii.2020.04.015Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–435. doi: https://doi.org/10.1016/j.jmii.2020.04.015Rice GI, Jones AL, Grant PJ, et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension. 2006;48(5):914–920. doi: https://doi.org/10.1161/01.HYP.0000244543.91937.79Rice GI, Jones AL, Grant PJ, et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension. 2006;48(5):914–920. doi: https://doi.org/10.1161/01.HYP.0000244543.91937.79Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. medRxiv. 2020;03.30.20047878. doi: https://doi.org/10.1101/2020.03.30.20047878Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. medRxiv. 2020;03.30.20047878. doi: https://doi.org/10.1101/2020.03.30.20047878Chaoxin J, Daili S, Yanxin H, et al. The influence of angiotensin-converting enzyme 2 gene polymorphisms on type 2 diabetes mellitus and coronary heart disease. Eur Rev Med Pharmacol Sci. 2013;17(19):2654–2659.Chaoxin J, Daili S, Yanxin H, et al. The influence of angiotensin-converting enzyme 2 gene polymorphisms on type 2 diabetes mellitus and coronary heart disease. Eur Rev Med Pharmacol Sci. 2013;17(19):2654–2659.Yang M, Zhao J, Xing L, Shi L. The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: A meta-analysis involving 14,122 patients. J Renin Angiotensin Aldosterone Syst. 2015;16(4):1240–1244. doi: https://doi.org/10.1177/1470320314549221Yang M, Zhao J, Xing L, Shi L. The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: A meta-analysis involving 14,122 patients. J Renin Angiotensin Aldosterone Syst. 2015;16(4):1240–1244. doi: https://doi.org/10.1177/1470320314549221Wu YH, Li JY, Wang C, et al. The ACE2 G8790A polymorphism: involvement in Type 2 diabetes mellitus combined with cerebral stroke. J Clin Lab Anal. 2017;31(2):e22033. doi: https://doi.org/10.1002/jcla.22033Wu YH, Li JY, Wang C, et al. The ACE2 G8790A polymorphism: involvement in Type 2 diabetes mellitus combined with cerebral stroke. J Clin Lab Anal. 2017;31(2):e22033. doi: https://doi.org/10.1002/jcla.22033Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: https://doi.org/10.1016/S2213-2600(20)30116-8Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: https://doi.org/10.1016/S2213-2600(20)30116-8Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa041. doi: https://doi.org/10.1093/jtm/taaa041Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa041. doi: https://doi.org/10.1093/jtm/taaa041Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801–1803. doi: https://doi.org/10.1093/eurheartj/ehaa235Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801–1803. doi: https://doi.org/10.1093/eurheartj/ehaa235Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260. https://doi.org/10.1038/s41569-020-0360-5Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260. https://doi.org/10.1038/s41569-020-0360-5Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(Pt 1):45–51. doi: https://doi.org/10.1042/BJ20040634Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(Pt 1):45–51. doi: https://doi.org/10.1042/BJ20040634Milne S, Yang CX, Timens W, et al. SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors. Lancet Respir Med. 2020;8(6):e50–e51. doi: https://doi.org/10.1016/S2213-2600(20)30224-1Milne S, Yang CX, Timens W, et al. SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors. Lancet Respir Med. 2020;8(6):e50–e51. doi: https://doi.org/10.1016/S2213-2600(20)30224-1Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020;41(19):1810–1817. doi: https://doi.org/10.1093/eurheartj/ehaa373.Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020;41(19):1810–1817. doi: https://doi.org/10.1093/eurheartj/ehaa373.de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705–1714. doi: https://doi.org/10.1016/S0140-6736(20)31030-8de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705–1714. doi: https://doi.org/10.1016/S0140-6736(20)31030-8Шестакова М.В., Викулова О.К., Исаков М.А., Дедов И.И. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации // Проблемы эндокринологии. — 2020. — Т. 66. — №1. — С. 112–123. [Shestakova MV. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the Russian diabetes registry. Problemy endocrinologii. 2020;66(1):112–123. (In Russ.)]. doi: https://doi.org/10.14341/probl12458Шестакова М.В., Викулова О.К., Исаков М.А., Дедов И.И. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации // Проблемы эндокринологии. — 2020. — Т. 66. — №1. — С. 112–123. [Shestakova MV. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the Russian diabetes registry. Problemy endocrinologii. 2020;66(1):112–123. (In Russ.)]. doi: https://doi.org/10.14341/probl12458Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. doi: https://doi.org/10.1161/CIRCRESAHA.120.317134Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. doi: https://doi.org/10.1161/CIRCRESAHA.120.317134Bean D, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020. doi: https://doi.org/10.1101/2020.04.07.20056788Bean D, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020. doi: https://doi.org/10.1101/2020.04.07.20056788Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;10.1002/ddr.21656. doi: https://doi.org/10.1002/ddr.21656Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;10.1002/ddr.21656. doi: https://doi.org/10.1002/ddr.21656Verdecchia P, Angeli F, Reboldi G. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. J Hypertens. 2020;38(6):1190–1191. doi: https://doi.org/10.1097/HJH.0000000000002469Verdecchia P, Angeli F, Reboldi G. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. J Hypertens. 2020;38(6):1190–1191. doi: https://doi.org/10.1097/HJH.0000000000002469Peiró C, Moncada S. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection? Circulation. 2020;141(21):1665–1666. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.047297Peiró C, Moncada S. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection? Circulation. 2020;141(21):1665–1666. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.047297

The authors declare that there are no conflicts of interest present.